CASE STUDY

RNA-Based Therapies 

Leverage customized bioanalytical approaches and efficient testing

Develop, test, and launch your RNA therapeutics with an all-inclusive approach that pairs scientific experts with a premier suite of bioanalytical platforms in state-of-the-art labs.  

When a complex ADA assay failed at two prior CROs, the sponsor turned to BioAgilytix for help. See how we applied a novel approach to overcome target interference challenges on a tight deadline.

What You'll Learn:
  • How BioAgilytix conducted the GCP study evaluating the drug for multiple indications.
  • An in-depth overview of the innovative solution BioAgilytix created to overcome target interference challenges caused by dimerization.
  • How the assay got back on track, and how this same solution can be applied to other studies, such as oncological programs.
Modality_ATMP_RNA1

Share this Resource

icon-twitter icon-linkedin link 1

Services

Complete Development and Testing Capabilities for Efficient Data Delivery

Therapeutic drugs and vaccines with RNA-based structures are relatively new in drug development, and the bioanalytical testing strategies for them are continuing to evolve.  Working with an experienced bioanalytical provider like BioAgilytix is a critical step to a successful preclinical and clinical approach.

Source multiple endpoints with just one service provider for your immunoassay, cell-based, molecular, and LC/MS assay development, validation, and sample testing. This approach helps ensure efficient data delivery for your therapeutic study.

PK Assays for RNA-based Therapeutics

Our scientific teams are well-versed in the unique methods and analytical platforms required for detection of nucleic acid-based therapeutics, such as mRNA, microRNA, siRNA, and aptamers, during both preclinical and clinical testing. Commonly utilized techniques include:

  • RT PCR (qPCR or ddPCR) for absolute and relative quantitation
  • Hybridization ELISAs
  • Ligand Binding Assays
  • LC/MS methods
      
Additional Bioanalytical Assay Services
Many RNA-based therapeutics include nucleic acid as well as a delivery system such as lipid nanoparticles (LNPs). In addition to PK measurements for the therapeutic itself, BioAgilytix provides immunogenicity for each of the drug components as well as biodistribution assays, biomarker testing, and CMC support for our clients with these types of modalities. Learn more about these service lines here: 
  • Humoral immunogenicity (ADA and NAb assays)
  • Preclinical biodistribution (RT-PCR)
  • Therapeutic protein expression (western blot, LC/MS, or LBA)
  • Target protein or gene expression (western blot, LC/MS, LBA, or RT-PCR)
  • Delivery system quantification (ex. LNP by LC/MS)
  • Biomarker assays
  • CMC bioanalytical
Comprehensive Suite of Bioanalytical Platforms

Premier suite of bioanalytical platforms to ensure the delivery of precise, robust, and reliable results for a wide range of assessments.

  • qPCR/ddPCR
  • ELISA
  • LC/MS
  • Flow cytometry 
  • MSD
Trust a Team of Scientific Experts to Deliver Cohesive, High-quality Bioanalytical Results
  • Benefit from working with a single team that drives both the assay development and sample testing
  • Work with Project Managers who directly coordinate all your critical assay work ensuring on-time deliverables according to your priorities and requirements

Share this Resource

icon-twitter icon-linkedin link 1

Our RNA-Based Services Include

Pharmacokinetics 

Rely on a team of experienced scientists to develop PK assays and generate reproducible and reliable results to support your drug program. 

Immunogenicity

Optimize drug safety with industry-leading immunogenicity and testing expertise to advance your program.

Biomarkers

Improve clinical trial efficacy and safety with comprehensive, fit-for-purpose biomarker analysis for your program.

Ready to Start Your Project?

Our scientists are available to discuss your RNA-based project and how our bioanalytical CRO can help you streamline the drug development process.